• Redwood City, CA


  • Aldo Carrascoso
  • Lieza Danan-Leon
  • Carlito Lebrilla
  • Carolyn Bertozzi


  • Founded 2016
  • Partnered 2018

A powerful new tool for precision medicine.

InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.